Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bio-Rad Laboratories, Inc. Class A Common Stock (NY:BIO)

295.43 +6.00 (+2.07%)
Official Closing Price Updated: 7:00 PM EDT, Sep 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Bio-Rad Laboratories, Inc. Class A Common Stock

< Previous 1 2 3 Next >
Bio-Rad's Management to Participate in Upcoming Investor Conferences
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad to Host Droplet Digital PCR Webinar on Tuesday, August 26, 2025
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad Reports Second-Quarter 2025 Financial Results
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad Appoints Rajat Mehta Executive Vice President, Global Commercial Operations
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad to Report Second Quarter 2025 Financial Results on Thursday, July 31, 2025
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad Expands Droplet Digital PCR Offering Through Strategic Acquisition and Platform Rollout
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad’s Management to Host Investor Meetings During Jefferies Global Healthcare Conference
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad's Management to Participate in Fireside Chat During 2025 RBC Capital Markets Global Healthcare Conference
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad Reports First-Quarter 2025 Financial Results
From Bio-Rad Laboratories, Inc.
Via Business Wire
Biodesix partner, Friends of Cancer Research, publishes data in Clinical Cancer Research, demonstrating strong association between ctDNA changes and treatment outcomes for patients with solid tumor types
Aggregate analysis of eight clinical trials of patients with advanced non-small cell lung cancer (aNSCLC) was supported by Biodesix, using Bio-Rad Droplet Digital™ PCR technology 
From Biodesix, Inc.
Via GlobeNewswire
Bio-Rad to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad Reports Fourth-Quarter and Full-Year 2024 Financial Results
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad Offers to Acquire Digital PCR Developer Stilla Technologies
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025
From Bio-Rad Laboratories, Inc.
Via Business Wire
Geneoscopy Closes $105M in Series C Funding Round to Power Next-Generation of Gastrointestinal Diagnostic Tests
From Geneoscopy, Inc.
Via Business Wire
Bio-Rad’s Management to Host Investor Meetings at J.P. Morgan's 43rd Annual Healthcare Conference
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad’s Management to Host Investor Meetings at Citi's 2024 Global Healthcare Conference
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad's Management to Participate in Fireside Chat During UBS Global Healthcare Conference
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad Reports Third-Quarter 2024 Financial Results
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024
From Bio-Rad Laboratories, Inc.
Via Business Wire
S&P 500 Shake-Up: New Entrants Driving Market Momentum
The quarterly rebalancing of the S&P 500 reflects market capitalization and performance shifts, highlighting growth and challenges in multiple sectors. 
Via MarketBeat
Topics Artificial Intelligence Stocks
Bio-Rad’s Management to Participate in Fireside Chat During Wells Fargo’s 2024 Healthcare Conference
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad Appoints Jon DiVincenzo President, Chief Operating Officer
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad Reports Second-Quarter 2024 Financial Results
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad to Report Second Quarter Financial Results on Thursday, August 1, 2024
From Bio-Rad Laboratories, Inc.
Via Business Wire
OncoCyte’s (NASDAQ:OCX) Innovative Approach: Potential in Precision Diagnostics
Via AB Newswire
OncoCyte's Innovative Approach: Potential in Precision Diagnostics
Chronic conditions such as organ transplant rejection and cancer represent significant challenges in modern healthcare, demanding precise diagnostic tools for effective management and treatment. For... 
Via TheNewswire.com
Bio-Rad Names Anette Engelhardt Executive Vice President and President of Clinical Diagnostics Group
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad’s Management to Participate in Fireside Chat During Jefferies Global Healthcare Conference
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad Reports First-Quarter 2024 Financial Results
From Bio-Rad Laboratories, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.